<DOC>
	<DOCNO>NCT00144378</DOCNO>
	<brief_summary>The median survival progression first-line chemotherapy metastatic gastric cancer 2.5 month . There data possible benefit second line therapy . reason trial investigate possible benefit chemotherapy compare best supportive care second line treatment urgently necessary . Irinotecan show response rate 20 % first line therapy high rate od disease stabilization . There trial investigate irinotecan second line set . Response rate 20 % report tis setting . Irinotecan supply without cost company Pfizer .</brief_summary>
	<brief_title>Irinotecan Versus Only Best Supportive Care Gastric Cancer</brief_title>
	<detailed_description>Metastatic gastric cancer , progressive disease one palliative chemotherapy Arm A : Irinotecan 250/350 mg/m2 q3w 1 . Cycle:250mg/m2/ 30min 2 . Cycle : If toxicity &gt; 2° CTC , Leuko-thrombopenia &gt; 3° occur , dose increase 350mg/m2 Arm B . Best supportive care</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Patient histologically proven adenocarcinoma stomach gastroesophageal junction Patient distant metastasis laparoscopically proven operative incurability locally advance gastric cancer patient tumor recurrence gastrectomy Patient progressive disease palliative firstline chemotherapy progressive disease within 6 month termination firstline chemotherapy , define objective progression image technique accord WHO criteria Age 18 75 year Sufficient liver function , define serumbilirubin &lt; 1,5 mg/dl ( 1,5 upper normal limit ) , ALT und AST &lt; 3x upper normal limit Sufficient renal function , define serum creatinine &lt; 1,25 x upper normal limit creatinine clearance &gt; 60ml/min calculated accord CrockroftGault Contraction patient reproductive potential KarnofskyIndex &gt; 60 % Measurable evaluable tumor manifestation Tumor progression later 6 month termination firstline chemotherapy KI 50 % le Patient already receive second line chemotherapy metastatic setting ( adjuvant chemotherapy one line palliative chemotherapy o allow , biologic prior therapy allow ) Prior current second malignancy despite basal carcinoma skin curatively treat carcinoma situ cervix Uncontrolled infection CNS metastases Other severe medical illness Prior major surgery le 2 week ago Parallel treatment another experimental therapy Parallel treatment another therapy aim tumor reduction Chronic diarrhea , subileus Chronic inflammatory bowel disease intestinal obstruction Pretreatment irinotecan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>irinotecan</keyword>
</DOC>